Supervisory Board

Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board

Dr Jörg Spiekerkötter is a member of PAION’s Supervisory Board since June 2007. Dr Jörg Spiekerkötter has many years of experience in the pharmaceutical industry where he has held executive positions in the areas of finance, law and human resources. Until May 2007, he was the Chief Financial Officer of Organon BioSciences N.V., Oss (Netherlands). He left after the acquisition of the company by the US pharmaceutical company Schering-Plough. Until September 2006, he was the Chief Financial Officer at Schering AG in Berlin (Germany), and before that Head of the Legal Department at Hoechst Schering AgrEvo GmbH in Berlin (Germany). Dr Spiekerkötter studied in Bielefeld (Germany), Lausanne (Switzerland) and Freiburg (Germany) and has a Ph.D. in law. Until December 2010, he was the Chief Financial Officer of Conergy AG, Hamburg (Germany). On 19 May 2010, PAION’s Supervisory Board appointed Dr Spiekerkötter as its Chairman.

Dr. Karin Louise Dorrepaal, Member of the Supervisory Board, Vice-Chairwoman of the Supervisory Board

Dr Karin Dorrepaal, member of PAION’s Supervisory Board since October 2012. She has broad experience in the Life Science Industry. Between 2004 and 2006, she was a member of the Management Board of Schering AG in Berlin. From 1990 to 2004 she worked as management consultant at Booz Allen & Hamilton in Amsterdam and New York. From 1985 until 1988 she was a Ph. D. Research Fellow at The Netherlands Cancer Institute in Amsterdam. .

John Dawson, Member of the Supervisory Board, Chairman of the Audit Committee

John Dawson is a member of PAION’s Supervisory Board since May 2014. He is Chief Executive Officer of Oxford BioMedica. From 1996 to 2007 he held senior management positions in the European operations of Cephalon Inc., including from 2005, a management board position as Chief Financial Officer and Head of Business Development Europe. In his time at Cephalon he led many of the deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to a turnover of several hundred million US dollars. In 2005 he led the US$360 million acquisition of Zeneus by Cephalon. Between 1991 and 1996 he was Director of Finance and Administration of Serono Laboratories (UK) Limited.